Laboratory Markets Innovative Test to Detect PEth in Newborn Blood Specimens
DES PLAINES, Ill., Feb. 5, 2018 /PRNewswire/ -- United States Drug Testing Laboratories, Inc. (USDTL), a pioneer in newborn forensic toxicology, alcohol biomarkers, and substances of abuse testing has announced a breakthrough in measuring Phosphatidylethanol (PEth) in newborn blood.
PEth is an abnormal phospholipid that is formed only in the presence of ethanol and has been reported in a number of tissues and fluids. Once produced in humans, it is incorporated into red blood cell membranes where no enzymatic or metabolic mechanism of elimination is available. PEth decomposes with a very predictable half-life of 4-5 days giving a detection window of up to approximately 2-4 weeks prior to collection.
PEth testing on a newborn may be done in the hospital setting shortly after birth. The dried blood spots, or whole blood, provide the hospitals with ample opportunity to choose the best time for specimen collection.
As part of Tampa General Hospital's (TGH) commitment to transforming health care through innovation, the academic health system collaborated with Manatee County and Archer First Response Systems (ArcherFRS) to accelerate response times to...
Today, Professor Francesco Muntoni, principal investigator of the international multicenter gene therapy trial for Duchenne Muscular Dystrophy with GNT0004 product, sponsored by Genethon, presented the innovative trial design and its initial results...
In this free webinar, attendees will gain insights into the clinical trial landscapes in China and Australia and discover practical strategies for maximizing collaboration and ensuring successful outcomes. This includes identifying common areas of...
Engage, Powered by ENA, on Tuesday announced a new partnership with Golisano Children's Hospital of Southwest Florida's emergency department that centers on enhancing the well-being and professional growth of emergency nurses who play an integral...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and...
Concert Health, the leading Collaborative Care platform, and the Advancing Integrated Mental Health Solutions (AIMS) Center in the University of Washington Department of Psychiatry and Behavioral Sciences, today announced a three year, multi-state...
